We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
Read MoreHide Full Article
Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu (NER1006).
A low volume (1L) polyethylene glycol-based bowel preparation, Plenvu, has been developed for whole bowel cleansing, with added focus on the ascending colon. This, in turn, is expected to enhance bowel cleansing and the overall experience relating to colonoscopy.
We note that Salix licensed the drug from Norgine in Aug 2016. The drug, upon approval, will offer the lowest solution for an FDA-approved bowel cleanser in the market. The drug will have an edge over high preparation volumes which sometimes can be a deterrent in patients completing their regimen.
In Apr 2015, Valeant acquired erstwhile Salix, a specialty pharmaceutical company with a portfolio of over 20 marketed products, including Xifaxan, Uceris, Apriso, Glumetza and Relistor to expand in gastrointestinal market.
Shares of Valeant Pharma have underperformed the Zacks classified Medical-Drugs industry in the last one year. The stock lost 14.8% against the industry’s 8.2% gain.
The approval of new drugs should boost Valeant’s top line. The company has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. Valeant started a rebuilding process with its new CEO, Joseph C. Papa in 2016. Even though it is still early to comment on the rebuilding process but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The dermatology business saw some positive trends as the average selling price stabilized. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force.
Zacks Rank and Stocks to Consider
Valeant Pharma carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Sanofi (SNY - Free Report) .
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company delivered positive earnings surprises in the trailing four quarters, with an average beat of 233.69%.
MEI Pharma’s estimates moved up from a loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the trailing four quarters, with an average beat of 66.56%. Sanofi’s earnings per share estimates increased from $3.00 to $3.18 for 2017 over last 60 days. The company posted positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Valeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
Valeant Pharmaceuticals International, Inc.'s wholly owned subsidiary, Salix Pharmaceuticals, announced that the FDA has accepted its New Drug Application for Plenvu (NER1006).
A low volume (1L) polyethylene glycol-based bowel preparation, Plenvu, has been developed for whole bowel cleansing, with added focus on the ascending colon. This, in turn, is expected to enhance bowel cleansing and the overall experience relating to colonoscopy.
We note that Salix licensed the drug from Norgine in Aug 2016. The drug, upon approval, will offer the lowest solution for an FDA-approved bowel cleanser in the market. The drug will have an edge over high preparation volumes which sometimes can be a deterrent in patients completing their regimen.
In Apr 2015, Valeant acquired erstwhile Salix, a specialty pharmaceutical company with a portfolio of over 20 marketed products, including Xifaxan, Uceris, Apriso, Glumetza and Relistor to expand in gastrointestinal market.
Shares of Valeant Pharma have underperformed the Zacks classified Medical-Drugs industry in the last one year. The stock lost 14.8% against the industry’s 8.2% gain.
The approval of new drugs should boost Valeant’s top line. The company has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. Valeant started a rebuilding process with its new CEO, Joseph C. Papa in 2016. Even though it is still early to comment on the rebuilding process but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable and should bode well in the upcoming quarters. The dermatology business saw some positive trends as the average selling price stabilized. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force.
Zacks Rank and Stocks to Consider
Valeant Pharma carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Sanofi (SNY - Free Report) .
While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Sanofi carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 60 days. The company delivered positive earnings surprises in the trailing four quarters, with an average beat of 233.69%.
MEI Pharma’s estimates moved up from a loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the trailing four quarters, with an average beat of 66.56%. Sanofi’s earnings per share estimates increased from $3.00 to $3.18 for 2017 over last 60 days. The company posted positive earnings surprises in three of the trailing four quarters, with an average beat of 5.10%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>